Article information
Full text is only aviable in PDF
References
[1.]
F. Illous, S. Laboureau-Soares, S. Duvois, V. Rohmer, P. Rodien.
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.
Eur J Endocrinol, 160 (2009), pp. 331-336
[2.]
N. Fuertes Zamorano, M. De Miguel Novoa, A. Molino González, J. Díaz Pérez, P. Martín Rojas-Marcos, M. Montañez Zorrilla.
Disfunción tiroidea en los pacientes con carcinoma de células renales avanzado en tratamiento con sunitinib: un problema multifactorial.
Endocrinol Nutr, (2010),
[3.]
E. Wong, L.S. Rosen, M. Mulay, A. Vanvugt, M. Dinolfo, C. Tomoda, et al.
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
Thyroid, 17 (2007), pp. 351-355
[4.]
D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P.G. Casali, et al.
A novel tyrosine kinase inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
J Clin Endocrinol Metab, 92 (2007), pp. 3531-3534
[5.]
I. Tamaskar, R. Bukowski, P. Elson, A.G. Ioachimescu, L. Wood, R. Dreicer, et al.
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Ann Oncol, 19 (2008), pp. 265-268
[6.]
F. Torino, S.M. Corsello, R. Longo, A. Barnabei, G. Gasparini.
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Nat Rev Clin Oncol, 6 (2009), pp. 219-228
[7.]
P. Wolter, C. Stefan, B. Decallonne, H. Dumez, M. Bex, P. Carmeliet, et al.
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Br J Cancer, 99 (2008), pp. 448-454
[8.]
D. Garfield, A. Hercbergs, P. Davis.
Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Nat Clin Pract Oncol, 12 (2007), pp. 674-675
[9.]
D.H. Garfield, A. Hercbergs, P.J. Davis.
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
J Natl Cancer Inst, 99 (2007), pp. 975-976
[10.]
E. Porlan, O.G. Vidaurre, A. Rodríguez-Peña.
Thyroid hormone receptor b (TR b1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2.
Oncogene, 27 (2008), pp. 2795-2798
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
